Myriad , MSK collaborate to study use of minimal residual disease testing

Myriad Genetics announced a collaboration with Memorial Sloan Kettering Cancer Center, MSK, to study the use of minimal residual disease testing in breast cancer. The research project will use Myriad’s MRD testing platform, a tumor-informed high-definition assay that uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA. Myriad is working together with Pedram Razavi, MD, PhD, a breast medical oncologist and Director of Liquid Biopsy & Genomics at MSK Global Biomarker Development Program. The MSK research team will investigate the use of MRD testing for patients in two breast cancer cohorts. The first will be in a metastatic patient population treated with CDK4/6 inhibitors and will evaluate the ability of MRD testing to predict treatment response. The second will be focused on the neoadjuvant setting and will assess the association of MRD testing with chemotherapy treatment response.